STN structure search - Registry / Caplus



G1 S, [@1] [Y]

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 full
FULL SEARCH INITIATED 14:33:17 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    25584 TO ITERATE

100.0% PROCESSED    25584 ITERATIONS                    167 ANSWERS
SEARCH TIME: 00.00.01

L2          167 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             172.10     172.31

FILE 'CAPLUS' ENTERED AT 14:33:20 ON 26 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 26 Feb 2007  VOL 146 ISS 10
FILE LAST UPDATED: 25 Feb 2007  (20070225/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
```

```
=> s l2
L3              18 L2

=> d ibib abs hitstr 1-18
```

L3 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1286266 CAPLUS
DOCUMENT NUMBER: 146:45497
TITLE: Anti-cytokine heterocyclic compounds as MAPKAP-K2 inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases
INVENTOR(S): Goldberg, Daniel; Abeywardane, Asitha; Miller, Craig; Morwick, Tina; Netherton, Matthew; Snow, Roger; Wang, Ji; Wu, Jiang-Ping; Xiong, Zhaoming
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 82pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006276496	A1	20061207	US 2006-276933	20060317
PRIORITY APPLN. INFO.:			US 2005-662936P P	20050317
			US 2005-719164P P	20050921

OTHER SOURCE(S): MARPAT 146:45497
GI


I


II

AB Heterocyclic compds. of formula I and analogs thereof and their use as inhibitors of Mitogen-Activated Protein Kinase-Activated Protein kinase-2 (MAPKAP-k2), and also to a method for preventing or treating a disease or disorder that can be treated or prevented by modulating the activity of MAPKAP-K2 in a subject and to pharmaceutical compns. and kits that include these MAPKAP-K2 inhibitors. Compds. of formula I wherein X is C and N; R1 is H, OH, carbamoyl, C1-6 alkyl, C2-6 alkenyl(oxy), C2-6 alkynyl(oxy), C1-6 alkoxy, etc.; R2 is absent, H, OH, ureido, C1-6 alkyl, C2-6 alkenyl(oxy), C2-6 alkynyl(oxy), C1-6 alkoxy, etc.; R3 is H, amino, C1-6 alkyl(amino), C2-6 alkenyl(oxy), C2-6 alkynyloxy, C1-6 alkynyl, etc.; R4 is absent, H, amino, C1-6 alkyl(amino), C2-6 alkenyl, CN, C1-6 alkynyl, etc.; R5 is absent, H, oxo, C1-6 (halo)alkyl, C2-6 alkenyl(oxy), C2-6 alkynyl(oxy), C1-6 alkoxy, OH, etc.; R6 is H, oxo, C1-6 (halo)alkyl, C2-6

L3 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

alkenyl(oxy), C2-6 alkynyl(oxy), oH, C3-7 cycloalkyl, etc.; R7 is H, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkoxy, OH, etc.; R8 is H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, and C3-7 cycloalkyl; R9 us H, halo, C1-6 alkyl, C2-6 alkenyl(oxy), C2-6 alkynyl(oxy), C1-6 alkoxy, etc.; R10 and R11 are independently H, C1-6 alkoxy, OH, halo, C1-6 alkyl, and C3-7 cycloalkyl; R12 is =S, =O, C1-6 alkyl, CN, aminoalkyl, amino, haloalkyl, etc.; R13 is absent, H, C1-6 alkyl, and halo; and their pharmaceutically acceptable salts are claimed. Example compd. II was prepd. by conjugate addn. of di-Et malonate to methacrylonitrile; the resulting 2-(2-cyano-2-methylethyl)malonic acid di-Et ester underwent cyclization to give 5-methyl-2-oxopiperidine-3-carboxylic acid Et ester, which underwent condensation with sodium nitrite and 4-aminobenzoic acid Et ester to give 4-[N'-(5-methyl-2-oxopiperidin-3-ylidene)hydrazino]benzoic acid Et ester, which underwent cyclization to give 4-methyl-1-oxo-2,3,4,9-tetrahydro-1H-β-carboline-6-carboxylic acid Et ester, which underwent hydrolysis to give compd. II. All the invention compds. were evaluated or their MAPKAP-K2 inhibitory activity.

IT 916520-88-2P 916520-89-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of anti-cytokine heterocyclic compds. as MAPKAP-K2 inhibitors useful in treatment and prevention of diseases)

RN 916520-88-2 CAPLUS
CN 1H-Carbazole-6-carboxamide, 1-[(aminocarbonyl)amino]-2,3,4,9-tetrahydro-N-3-pyridinyl- (CA INDEX NAME)



RN 916520-89-3 CAPLUS
CN 1H-Carbazole-6-carboxamide, 1-(acetylamino)-2,3,4,9-tetrahydro-N-3-pyridinyl- (CA INDEX NAME)



L3 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1207230 CAPLUS
DOCUMENT NUMBER: 145:500040
TITLE: Treatment or prophylaxis of Flaviviridae viruses using substituted 2,3,4,9-tetrahydro-1H-carbazoles and related compounds
INVENTOR(S): Gudmundsson, Kristjan
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 70pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006121466	A2	20061116	WO 2005-US41090	20051114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			US 2004-629906P P	20041122

OTHER SOURCE(S): MARPAT 145:500040
GI


I

AB The present invention relates to 2,3,4,9-tetrahydro-1H-carbazoles and related compds. (shown as I; variables defined below; e.g. N-benzyl-2,3,4,9-tetrahydrocarbazol-1-amine hydrochloride) that are useful in the treatment of viruses belonging to Flaviviridae, including flaviviruses, pestiviruses, and hepaciviruses. The invention includes compds. useful for the treatment or prophylaxis of dengue fever, yellow fever, West Nile virus, and HCV. For I: n = 0-2; R is H or alkyl; X is NR2, O, or S(O)m; each R1 = H, halogen, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, -R10cycloalkyl, Ay, -NHR10Ay, Het, -NHHet, -NHR10Het, -OR2, -OAy, - OHet, -R10OR2, -NR2R3, -NR2Ay, -R10NR2R3, et al.; Y is (un)substituted alkylene, cycloalkylene, alkenylene, cycloalkenylene, or alkynylene; d = 0-1; Z is -R2, -OR2, -C(O)R2,

L3 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
-C(O)2R2, -S(O)mR2, -C(O)NR2R3, -Het, or Ay, provided when d is 0, then Z is not -Het or -Ay; each m = 0-2; each R10 = alkylene, cycloalkylene, alkenylene, cycloalkenylene, and alkynylene; p = 0-4; each of R2 and R3 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, -R10cycloalkyl, -R10OH, -R10(OR10)w, and -R10NR5R6; w = 1-10; each of R5 and R6 = alkyl, cycloalkyl, alkenyl, cycloalkenyl, and alkynyl; Ay = (un)substituted aryl;
Het = (un)substituted 5- or 6-membered heterocyclyl or heteroaryl group; addnl. details are given in the claims. Inhibition of HCV activity was measure for 3 examples of I, e.g. IC50 = 8 nM for (1R)-6-Bromo-N-((1S)-1-phenylethyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride. Although the methods of prepn. are not claimed, prepns. and/or characterization data for apprx.70 examples of I are included. For example, N-benzyl-2,3,4,9-tetrahydrocarbazol-1-amine hydrochloride was prepd. (35 % yield) by addn. of sodium triacetoxyborohydride, acetic acid and benzylamine to a dichloroethane soln. of 2,3,4,9-tetrahydro-1H-carbazol-1-one, which was prepd. in 2 steps from 4-chloroaniline, NaNO2 and 2-(hydroxymethylene)cyclohexanone in which the intermediate cyclohexane-1,2-dione (4-chlorophenyl)hydrazone was cyclized.
IT 847988-53-8P, 1-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-3-isopropylurea 847988-54-9P 847988-55-0P, N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)acetamide 847988-56-1P, N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)cyclohexanecarboxamide 847988-57-2P, N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)methanesulfonamide 847988-59-4P, 1-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; treatment or prophylaxis of Flaviviridae viruses using substituted 2,3,4,9-tetrahydro-1H-carbazoles and related compds.)
RN 847988-53-8 CAPLUS
CN Urea, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 847988-54-9 CAPLUS
CN Carbamic acid, (6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-, methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 847988-59-4 CAPLUS
CN Urea, (6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



L3 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 847988-55-0 CAPLUS
CN Acetamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 847988-56-1 CAPLUS
CN Cyclohexanecarboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 847988-57-2 CAPLUS
CN Methanesulfonamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI)
(CA INDEX NAME)

L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1179153 CAPLUS
DOCUMENT NUMBER: 145:465666
TITLE: Tetrahydrocarbazoles useful as inhibitors of hepatitis C and other viruses belonging to Flaviviridae
INVENTOR(S): Gudmundsson, Kristjan; Samano, Vicente
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 69pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006118607	A2	20061109	WO 2005-US41089	20051114

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-629905P P 20041122

OTHER SOURCE(S): MARPAT 145:465666
GI



I



II

AB The present invention relates to tetrahydrocarbazoles [shown as I; n = 0-2; t = 0 or 1; X = NH, O, -R10-, -OR10-, -R10O-, -R10OR10-, NR10-, -R10N-, -R10NR10-, -R10S(O)m-, or R10S(O)mR10-; Y = C(O), S(O)m; R and R1

L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
independently = halo, haloalkyl, alk(en/yn)yl, cycloalkyl, cyano, nitro or
azido, et al.; m = 0-2; R10 = alkylene, cycloalkylene, alkenylene, cycloalkenylene, and alkynylene; p, q = 0-5; A = (hetero)aryl; addnl. details including provisos are given in the claims; or salts, solvates and
physiol. functional derivs. thereof] that are useful in the treatment of viruses belonging to Flaviviridae, including flaviviruses, pestiviruses, and hepaciviruses. The invention includes compds. useful for the treatment or prophylaxis of dengue fever, yellow fever, West Nile virus, and HCV. Although the methods of prepn. are not claimed, prepns. and/or characterization data for .apprx.70 examples of I are included. For example, 6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-amine was reacted with picolinoyl chloride to give II as a racemate in 63% yield, which was then sepd. into two pure enantiomers by supercrit. fluid chromatog. IC50 values for inhibition of HCV activity are tabulated for 6 examples of I, e.g. 6 nM for (R)-II.
IT 827590-44-3P 827590-77-2P 827591-00-4P
827591-06-0P
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical
process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(drug candidate; tetrahydrocarbazoles useful as inhibitors of hepatitis
C and other viruses belonging to Flaviviridae)
RN 827590-44-3 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 827590-77-2 CAPLUS
CN Benzamide, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827591-00-4 CAPLUS
CN 2-Pyridinecarboxamide, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 827591-06-0 CAPLUS
CN Benzamide, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2-fluoro- (9CI) (CA INDEX NAME)



IT 827590-45-4P 827590-46-5P 827590-79-4P
827590-81-8P 827591-02-6P 827591-08-2P
827591-10-6P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN

L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; tetrahydrocarbazoles useful as inhibitors of hepatitis
C and other viruses belonging to Flaviviridae)
RN 827590-45-4 CAPLUS
CN Benzamide, N-[(1R)-6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827590-46-5 CAPLUS
CN Benzamide, N-[(1S)-6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827590-79-4 CAPLUS
CN Benzamide, N-[(1R)-6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 827590-81-8 CAPLUS
CN Benzamide, N-[(1S)-6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827591-02-6 CAPLUS
CN 2-Pyridinecarboxamide, N-[(1R)-6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 827591-08-2 CAPLUS
CN Benzamide,
N-[(1R)-6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl]-2-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827591-10-6 CAPLUS
CN Benzamide,
N-[(1S)-6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl]-2-fluoro- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



IT 913961-57-6P, Methyl 6-[[(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino]carbonyl]-3-pyridinecarboxylate 913961-58-7P, 6-[[(6-Chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino]carbonyl]-3-pyridinecarboxylic acid 913961-59-8P, 1,1-Dimethylethyl [2-[[2-[[2-[[[6-[[(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino]carbonyl]-3-pyridinyl]carbonyl]amino]ethyl]oxy]ethyl]oxy]ethyl]carbamate 913961-60-1P, N'-[2-[[2-[(2-Aminoethyl)oxy]ethyl]oxy]ethyl]-N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2,5-pyridinedicarboxamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; tetrahydrocarbazoles useful as inhibitors of hepatitis C and other viruses belonging to Flaviviridae)

RN 913961-57-6 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[[(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 913961-60-1 CAPLUS
CN 2,5-Pyridinedicarboxamide, N5-[2-[2-(2-aminoethoxy)ethoxy]ethyl]-N2-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



IT 827590-39-6P 827590-40-9P 827590-41-0P
827590-42-1P 827590-43-2P 827590-47-6P
827590-48-7P 827590-49-8P 827590-50-1P
827590-51-2P 827590-52-3P 827590-53-4P
827590-54-5P 827590-55-6P 827590-56-7P
827590-57-8P 827590-58-9P 827590-59-0P
827590-61-4P 827590-63-6P 827590-65-8P
827590-67-0P 827590-69-2P 827590-71-6P
827590-73-8P 827590-75-0P 827590-83-0P
827590-85-2P 827590-87-4P 827590-89-6P
827590-91-0P 827590-94-3P 827590-96-5P
827590-98-7P 827591-04-8P 827591-12-8P
827591-14-0P 827591-17-3P 827591-19-5P
827591-21-9P 827591-23-1P 827591-25-3P
827591-28-6P 893410-67-8P, N-(6-Chloro-2,3,4,9-

L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 913961-58-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[[(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 913961-59-8 CAPLUS
CN 5,8-Dioxa-2,11-diazadodecanoic acid, 12-[6-[[(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino]carbonyl]-3-pyridinyl]-12-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
tetrahydro-1H-carbazol-1-yl)-2-furancarboxamide 913961-47-4P, N-(6-Chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2-pyrazinecarboxamide 913961-48-5P, N-(6-Chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-6-methyl-2-pyridinecarboxamide 913961-49-6P, N-(6-Chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)isoxazole-5-carboxamide 913961-50-9P, N-(6-Chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-3,5-dimethylisoxazole-4-carboxamide 913961-51-0P, N-(6-Chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-6-fluoro-2-pyridinecarboxamide 913961-52-1P, N-(6-Chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-3-methylpyridine-2-carboxamide 913961-53-2P, N-[2-[[2-[(2-Aminoethyl)oxy]ethyl]oxy]ethyl]-N'-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-1,4-benzenedicarboxamide 913961-61-2P, N-(6-Chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-N'-[2-[[2-[[2-[(phenylcarbonyl)amino]ethyl]oxy]ethyl]oxy]ethyl]-2,5-pyridinedicarboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; tetrahydrocarbazoles useful as inhibitors of hepatitis C and other viruses belonging to Flaviviridae)

RN 827590-39-6 CAPLUS
CN Urea, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-N'-phenyl- (9CI) (CA INDEX NAME)



RN 827590-40-9 CAPLUS
CN Urea, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-N'-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827590-41-0 CAPLUS
CN Urea, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-N'-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 827590-42-1 CAPLUS
CN Urea, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-N'-(3-chloro-4-methoxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827590-43-2 CAPLUS
CN Urea, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-N'-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)



RN 827590-47-6 CAPLUS
CN Benzeneacetamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827590-48-7 CAPLUS
CN Benzenepropanamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 827590-49-8 CAPLUS
CN 2-Propenamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-3-phenyl- (9CI) (CA INDEX NAME)



RN 827590-50-1 CAPLUS
CN Carbamic acid, (6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 827590-51-2 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2,6-dichloro-

L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(9CI) (CA INDEX NAME)



RN 827590-52-3 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-fluoro- (9CI) (CA INDEX NAME)



RN 827590-53-4 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-methoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827590-54-5 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-nitro- (9CI) (CA INDEX NAME)



RN 827590-55-6 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-chloro- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827590-56-7 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-methyl- (9CI) (CA INDEX NAME)



RN 827590-57-8 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827590-58-9 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-3-fluoro- (9CI) (CA INDEX NAME)



RN 827590-59-0 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-3-methoxy- (9CI) (CA INDEX NAME)



L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 827590-61-4 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-3-methyl- (9CI) (CA INDEX NAME)



RN 827590-63-6 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2-fluoro- (9CI) (CA INDEX NAME)



RN 827590-65-8 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2-methoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827590-67-0 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2-nitro- (9CI) (CA INDEX NAME)



RN 827590-69-2 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2-chloro- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827590-83-0 CAPLUS
CN Benzenesulfonamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-methyl- (9CI) (CA INDEX NAME)



RN 827590-85-2 CAPLUS
CN 2-Pyridinecarboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 827590-87-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827590-71-6 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2-methyl- (9CI) (CA INDEX NAME)



RN 827590-73-8 CAPLUS
CN Benzamide, N-(2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 827590-75-0 CAPLUS
CN Benzamide, N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827590-89-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-6-chloro- (9CI) (CA INDEX NAME)



RN 827590-91-0 CAPLUS
CN 4-Pyridinecarboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 827590-94-3 CAPLUS
CN Urea, N-phenyl-N'-(2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX

L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
NAME)



RN 827590-96-5 CAPLUS
CN Urea, N-phenyl-N'-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 827590-98-7 CAPLUS
CN Urea, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-N'-phenyl- (9CI) (CA INDEX NAME)



RN 827591-04-8 CAPLUS
CN 2-Pyridinecarboxamide, N-[(1S)-6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827591-19-5 CAPLUS
CN 1H-Imidazole-4-carboxamide, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 827591-21-9 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827591-12-8 CAPLUS
CN 1H-Imidazole-5-carboxamide, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-1-methyl- (9CI) (CA INDEX NAME)



RN 827591-14-0 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-1-methyl- (9CI) (CA INDEX NAME)



RN 827591-17-3 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-1-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 827591-23-1 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 827591-25-3 CAPLUS
CN Benzenesulfonamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 827591-28-6 CAPLUS
CN Benzenesulfonamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2-fluoro- (9CI) (CA INDEX NAME)



L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 893410-67-8 CAPLUS
CN 2-Furancarboxamide, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-(9CI) (CA INDEX NAME)



RN 913961-47-4 CAPLUS
CN Pyrazinecarboxamide, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-(9CI) (CA INDEX NAME)



RN 913961-48-5 CAPLUS
CN 2-Pyridinecarboxamide, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-6-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 913961-49-6 CAPLUS
CN 5-Isoxazolecarboxamide, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-(9CI) (CA INDEX NAME)



RN 913961-50-9 CAPLUS
CN 4-Isoxazolecarboxamide, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-3,5-dimethyl- (9CI) (CA INDEX NAME)



L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 913961-51-0 CAPLUS
CN 2-Pyridinecarboxamide, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-6-fluoro- (9CI) (CA INDEX NAME)



RN 913961-52-1 CAPLUS
CN 2-Pyridinecarboxamide, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-3-methyl- (9CI) (CA INDEX NAME)



RN 913961-53-2 CAPLUS
CN 1,4-Benzenedicarboxamide, N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]-N'-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 913961-61-2 CAPLUS
CN 2,5-Pyridinedicarboxamide, N2-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-N5-(1,12-dioxo-12-phenyl-5,8-dioxa-2,11-diazadodec-1-yl)- (9CI) (CA INDEX NAME)



IT 913961-56-5P, 1,1-Dimethylethyl [2-[[2-[[2-[[[4-[[(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino]carbonyl]phenyl]carbonyl]amino]ethyl]oxy]ethyl]oxy]ethyl]carbamate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(tetrahydrocarbazoles useful as inhibitors of hepatitis C and other viruses belonging to Flaviviridae)

RN 913961-56-5 CAPLUS
CN 5,8-Dioxa-2,11-diazadodecanoic acid, 12-[4-[[(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino]carbonyl]phenyl]-12-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L3 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:608619 CAPLUS
DOCUMENT NUMBER: 145:83213
TITLE: Preparation of tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control
INVENTOR(S): Lennox, William Joseph; Qi, Hongyan; Lee, Duck-Hyung; Choi, Soongyu; Moon, Young-Choon
PATENT ASSIGNEE(S): PTC Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 137 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006065480	A2	20060622	WO 2005-US42483	20051123
WO 2006065480	A3	20060803		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:		
US 2004-629889P	P	20041123
US 2004-633738P	P	20041206
US 2004-639283P	P	20041227

OTHER SOURCE(S): MARPAT 145:83213
GI

L3 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I II

III IV

AB The present invention relates to methods, compds., and compns. for inhibiting angiogenesis. More particularly, the present invention relates to methods, compds., and compns. for inhibiting VEGF production The title compds. I [X = NR9R10, N(alkyl)C(O)aryl, H, etc. (wherein R9, R10 = H, alkyl, aryl, etc.; or NR9R10 = mono- or bicyclic heterocyclic ring); R1-R3 = H, OH, alkyl (wherein R1 may optionally form (un)substituted 5-11 membered mono- or bi-heterocyclic ring with X); n = 0-2; R4-R7 = H, OH, alkyl, etc.; W = N, O, S; R8 = H, alkyl, cycloalkyl, etc.; with the provision] were prepared Thus, reacting amine II with 2,3-diformylthiophene followed by treating the intermediate lactam III with LAH in THF afforded IV which showed EC50 of <0.01 μM in an assay evaluating the ability of compds. I to modulate hypoxia-inducible endogenous VEGF expression.

IT 827590-39-6P 827590-44-3P 827590-53-4P
827590-55-6P 827590-57-8P 827590-87-4P
827590-89-6P 893409-78-4P 893409-84-2P
893409-89-7P 893409-92-2P 893409-98-8P
893410-20-3P 893410-21-4P 893410-34-9P
893410-52-1P 893410-53-2P 893410-54-3P
893410-55-4P 893410-56-5P 893410-57-6P
893410-59-8P 893410-60-1P 893410-66-7P
893410-67-8P 893410-68-9P 893410-69-0P
893410-70-3P 893410-73-6P 893410-74-7P
893410-75-8P 893410-76-9P 893410-77-0P
893410-78-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control)

L3 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 827590-39-6 CAPLUS
CN Urea, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-N'-phenyl- (9CI) (CA INDEX NAME)



RN 827590-44-3 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 827590-53-4 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-methoxy- (9CI) (CA INDEX NAME)



RN 827590-55-6 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-chloro- (9CI)
(CA INDEX NAME)

L3 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827590-57-8 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827590-87-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 893409-84-2 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-3-phenoxy- (9CI) (CA INDEX NAME)



RN 893409-89-7 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-phenoxy- (9CI) (CA INDEX NAME)



RN 893409-92-2 CAPLUS

L3 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827590-89-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-6-chloro- (9CI) (CA INDEX NAME)



RN 893409-78-4 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-3-chloro- (9CI)
(CA INDEX NAME)

L3 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2,3-dimethoxy- (9CI) (CA INDEX NAME)



RN 893409-98-8 CAPLUS
CN Benzenesulfonamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI)
(CA INDEX NAME)



RN 893410-20-3 CAPLUS
CN Pyrazinecarboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 893410-21-4 CAPLUS
CN Carbamic acid, (6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-, phenyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 893410-34-9 CAPLUS
CN 1,2,3-Thiadiazole-5-carboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-methyl- (9CI) (CA INDEX NAME)



RN 893410-52-1 CAPLUS
CN 2-Furancarboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 893410-53-2 CAPLUS
CN 2-Benzofurancarboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 893410-56-5 CAPLUS
CN 1H-Indole-2-carboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 893410-57-6 CAPLUS
CN 2-Thiophenecarboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 893410-59-8 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-cyano- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 893410-54-3 CAPLUS
CN 2-Furancarboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-5-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 893410-55-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 893410-60-1 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2,4-difluoro- (9CI) (CA INDEX NAME)



RN 893410-66-7 CAPLUS
CN 2-Thiophenecarboxamide, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



L3 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 893410-67-8 CAPLUS
CN 2-Furancarboxamide, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-(9CI) (CA INDEX NAME)



RN 893410-68-9 CAPLUS
CN Benzamide, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-methoxy-(9CI) (CA INDEX NAME)



RN 893410-69-0 CAPLUS
CN 2-Furancarboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-5-nitro- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 893410-70-3 CAPLUS
CN Cyclopropanecarboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-(9CI) (CA INDEX NAME)



RN 893410-73-6 CAPLUS
CN 5-Isoxazolecarboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-(9CI) (CA INDEX NAME)



L3 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 893410-74-7 CAPLUS
CN 3-Isoxazolecarboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-5-methyl- (9CI) (CA INDEX NAME)



RN 893410-75-8 CAPLUS
CN 3-Furancarboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-(9CI)
(CA INDEX NAME)



RN 893410-76-9 CAPLUS
CN 3-Thiophenecarboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-(9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 893410-77-0 CAPLUS
CN 2-Thiophenecarboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-5-chloro- (9CI) (CA INDEX NAME)



RN 893410-78-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-1-methyl- (9CI) (CA INDEX NAME)



IT 415939-77-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

L3 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(Biological study); USES (Uses)
(prepn. of tetrahydrocarbazoles as active agents for inhibiting VEGF prodn. by translational control)
RN 415939-77-4 CAPLUS
CN Acetamide, N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



IT 893411-30-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tetrahydrocarbazoles as active agents for inhibiting VEGF
production by translational control)
RN 893411-30-8 CAPLUS
CN Carbamic acid, (6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L3 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L3 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1123738 CAPLUS
DOCUMENT NUMBER: 143:399826
TITLE: Nuclear protein export inhibitors for the treatment of cardiac hypertrophy and heart failure
INVENTOR(S): McKinsey, Timothy
PATENT ASSIGNEE(S): Myogen, Inc., USA
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097088	A2	20051020	WO 2005-US11264	20050405
WO 2005097088	A3	20060112		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, US				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2561954	A1	20051020	CA 2005-2561954	20050405
US 2005288215	A1	20051229	US 2005-99417	20050405
EP 1734999	A2	20061227	EP 2005-763477	20050405
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: US 2004-559493P P 20040405
WO 2005-US11264 W 20050405

AB The invention provides methods for treating cardiac hypertrophy by administering a drug that is known to be a non-selective inhibitor of nuclear protein export to a patient in need thereof. The nuclear protein export inhibitor may be e.g. leptomycin B.
IT 413593-64-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nuclear protein export inhibitors for treatment of cardiac hypertrophy
and heart failure)
RN 413593-64-3 CAPLUS
CN Acetamide, 2-chloro-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:371222 CAPLUS
DOCUMENT NUMBER: 142:430133
TITLE: Preparation of carbazoles and related compounds as antiviral agents
INVENTOR(S): Ni, Zhi-Jie; Chang, Bryan; Wang, Weibo; Weiner, Amy
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005037791	A1	20050428	WO 2004-US34169	20041015
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1678137	A1	20060712	EP 2004-795347	20041015
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.: US 2003-511769P P 20031015
WO 2004-US34169 W 20041015

OTHER SOURCE(S): MARPAT 142:430133
GI



I

AB Title compds. I [R1 = H, halo, formyl, etc.; R2 = heteroaryl, arylalkyl, alkyl, etc.; R7 = H, NH2, alkyl, etc.; R9 = H, alkyl; n = 1-4; p = 0-2] and their pharmaceutically acceptable salts were prepared. For example, reductive amination of 6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-one, e.g.,
prepared from 4-bromoaniline, with cyclohexylamine afforded 6-bromo-N-cyclohexyl-2,3,4,9-tetrahydro-1H-carbazole-1-amine (II). In HCV
inhibition assays, compound II·CF3CO2H showed activity at <4 μM. Compds. I are claimed useful for the treatment of HCV, SARS, etc.

L3 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

IT 352549-64-5P 415939-77-4P 419557-61-2P
827590-75-0P 851054-05-2P 851054-06-3P
851054-07-4P 851054-11-0P 851054-17-6P
851054-23-4P 851054-24-5P 851054-25-6P
851054-32-5P 851054-33-6P 851054-34-7P
851054-35-8P 851054-43-8P 851054-54-1P
851054-58-5P 851054-60-9P 851054-63-2P
851054-64-3P 851054-65-4P 851054-72-3P
851054-76-7P 851054-77-8P 851054-80-3P
851054-81-4P 851054-90-5P 851054-91-6P
851055-03-3P 851055-20-4P 851055-24-8P
851055-35-1P 851055-82-8P 851055-83-9P
851055-84-0P 851055-85-1P 851055-86-2P
851055-87-3P 851056-11-6P 851056-12-7P
851056-13-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of carbazoles and related compds. as antiviral agents for treatment of HCV, SARS, etc.)

RN 352549-64-5 CAPLUS
CN Urea, (6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 415939-77-4 CAPLUS
CN Acetamide, N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 419557-61-2 CAPLUS
CN Urea, (2,3,4,9-tetrahydro-1,6-dimethyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851054-07-4 CAPLUS
CN Cyclobutanecarboxamide, N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 851054-11-0 CAPLUS
CN Cyclopentanecarboxamide, N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 851054-17-6 CAPLUS
CN Cyclopentaneacetamide, N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827590-75-0 CAPLUS
CN Benzamide, N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 851054-05-2 CAPLUS
CN Propanamide, N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 851054-06-3 CAPLUS
CN Cyclopropanecarboxamide, N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851054-23-4 CAPLUS
CN Benzamide, 3-fluoro-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 851054-24-5 CAPLUS
CN Benzamide, 4-fluoro-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



L3 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 851054-25-6 CAPLUS
CN Benzamide, 2-fluoro-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)-(9CI) (CA INDEX NAME)



RN 851054-32-5 CAPLUS
CN Benzamide, 2-cyano-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)-(9CI)
(CA INDEX NAME)



RN 851054-33-6 CAPLUS
CN Benzamide, 4-cyano-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)-(9CI)
(CA INDEX NAME)

L3 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851054-34-7 CAPLUS
CN Benzamide, 3-cyano-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)-(9CI)
(CA INDEX NAME)



RN 851054-35-8 CAPLUS
CN Benzamide, 2,4-dimethyl-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)-(9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851054-43-8 CAPLUS
CN Benzamide, 3,4-difluoro-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)-(9CI) (CA INDEX NAME)



RN 851054-54-1 CAPLUS
CN Benzamide,
3-fluoro-4-methoxy-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851054-58-5 CAPLUS
CN Benzenesulfonamide,
4-methyl-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 851054-60-9 CAPLUS
CN Benzenesulfonamide,
2-fluoro-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851054-63-2 CAPLUS
CN Benzenesulfonamide, 2-cyano-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 851054-64-3 CAPLUS
CN Benzenesulfonamide, 4-cyano-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851054-65-4 CAPLUS
CN Benzenesulfonamide, 3-cyano-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 851054-72-3 CAPLUS
CN Benzamide, 3-chloro-4-methoxy-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851054-76-7 CAPLUS
CN Benzamide, N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 851054-77-8 CAPLUS
CN Benzamide, N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 851054-80-3 CAPLUS

L3 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Benzenesulfonamide, 3-chloro-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 851054-81-4 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 851054-90-5 CAPLUS
CN Benzamide, 3-bromo-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851054-91-6 CAPLUS
CN Urea, N-(2,4-dichlorophenyl)-N'-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 851055-03-3 CAPLUS
CN Benzenesulfonamide, 4-butyl-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851055-20-4 CAPLUS
CN Benzenesulfonamide, 4-bromo-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 851055-24-8 CAPLUS
CN Benzenesulfonamide, N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851055-35-1 CAPLUS
CN Benzamide, 3-iodo-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 851055-82-8 CAPLUS
CN Benzamide, 2,4-dimethoxy-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851055-83-9 CAPLUS
CN Benzamide, 2,4-dichloro-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 851055-84-0 CAPLUS
CN Benzamide, 2-bromo-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851055-85-1 CAPLUS
CN Benzamide, 2-iodo-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 851055-86-2 CAPLUS
CN Butanamide, N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 851055-87-3 CAPLUS
CN Propanamide, 2-methyl-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L3 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851056-11-6 CAPLUS
CN 1-Propanesulfonamide, N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 851056-12-7 CAPLUS
CN Urea, N-(3,4-difluorophenyl)-N'-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 851056-13-8 CAPLUS
CN Urea, N-(4-iodophenyl)-N'-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:232610 CAPLUS
DOCUMENT NUMBER: 142:316689
TITLE: Preparation of novel cycloalkyl[b] condensed indoles for treating human papillomaviruses
INVENTOR(S): Boggs, Sharon Davis; Catalano, John G.; Gudmundsson, Kristjan S.; D'Aurora Richardson, Leah; Sebahar, Paul Richard
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005023245	A1	20050317	WO 2004-US17982	20040607
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1658068	A1	20060524	EP 2004-754553	20040607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007503434	T	20070222	JP 2006-524621	20040607
US 2006281804	A1	20061214	US 2006-569524	20060224
PRIORITY APPLN. INFO.:			US 2003-497845P	P 20030826
			WO 2004-US17982	W 20040607

OTHER SOURCE(S): MARPAT 142:316689
GI



AB The present invention relates to cycloalkyl[b] condensed indoles (shown as I; variables defined below; e.g. 6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-amine), including administration of pharmaceutically acceptable salts, solvates, and physiol. functional derivs. thereof, that are useful in the

L3 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

treatment of human papillomaviruses (HPVs), and also to the methods for the making and use of such compds. HPV inhibition values for 56 examples of I are reported. For I: n = 0-2; R is H or alkyl; X is NR2, O, or S(O)m; each R1 = H, halogen, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, R10cycloalkyl, Ay, NHR10Ay, Het, NHHet, NHR10Het, OR2, OAy, OHet, R10OR2, NR2R3, NR2Ay, R10NR2R3, R10NR2Ay, R10C(O)R2, C(O)R2, CO2R2, R10CO2R2, C(O)NR2R3, C(O)Ay, C(O)NR2Ay, C(O)Het, C(O)NHR10Het, R10C(O)NR2R3, C(S)NR2R3, R10C(S)NR2R3, R10NHC(NH)NR2R3, C(NH)NR2R3, R10C(NH)NR2R3, S(O)2NR2R3, S(O)2NR2Ay, R10SO2NHCOR2, ROSO2NR2R3, R10SO2R2, S(O)mR2, cyano, nitro, or azido. Y is (un)substituted alkylene, (un)substituted cycloalkylene, (un)substituted alkenylene, (un)substituted cycloalkenylene, or (un)substituted alkynylene; d = 0-1; Z is R2, OR2, C(O)R2, C(O)2R2, S(O)mR2, C(O)NR2R3, Het, or Ay, provided when d is 0, then Z is not Het or Ay; each m = 0-2; each R10 = alkylene, cycloalkylene, alkenylene, cycloalkenylene, and alkynylene; p = 0-4; each of R2 and R3 H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, R10cycloalkyl, R10OH, R10(OR10)w, and R10NR5R6; w = 1-10; each of R5 and R6 = alkyl, cycloalkyl, alkenyl, cycloalkenyl, and alkynyl; Ay = (un)substituted aryl; Het = (un)substituted 5- or 6-membered heterocyclyl or heteroaryl. Although the methods of prepn. are not claimed, .apprx.70 example prepns. are included. For example, 6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-amine was prepd. (52 %) from 6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-one, NH4OAc, and NaBH3CN in MeOH; the ketone was prepd. (88 %) by cyclization of cyclohexane-1,2-dione (4-chlorophenyl)hydrazone, which was prepd. (49 %) from the diazonium salt of 4-chloroaniline and 2-(hydroxymethylene)cyclohexanone.

IT 847988-53-8P, 1-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-3-isopropylurea 847988-54-9P, Methyl (6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)carbamate 847988-55-0P, N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)acetamide 847988-56-1P, N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)cyclohexanecarboxamide 847988-57-2P, N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)methanesulfonamide 847988-59-4P, 1-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of novel cycloalkyl[b] condensed indoles for treating human papillomaviruses)

RN 847988-53-8 CAPLUS
CN Urea, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 847988-54-9 CAPLUS
CN Carbamic acid, (6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-, methyl ester (9CI) (CA INDEX NAME)



RN 847988-55-0 CAPLUS
CN Acetamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 847988-56-1 CAPLUS
CN Cyclohexanecarboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 847988-57-2 CAPLUS
CN Methanesulfonamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 847988-59-4 CAPLUS
CN Urea, (6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:55201 CAPLUS
DOCUMENT NUMBER: 142:155815
TITLE: Preparation of tetrahydrocarbazoles useful in the treatment of diseases associated with human papillomavirus infection
INVENTOR(S): Boggs, Sharon Davis; Gudmundsson, Kristjan
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

Instant App.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005005386	A1	20050120	WO 2004-US18180	20040607
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004256052	A1	20050120	AU 2004-256052	20040607
CA 2528336	A1	20050120	CA 2004-2528336	20040607
EP 1646610	A1	20060419	EP 2004-776370	20040607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1802354	A	20060712	CN 2004-80016013	20040607
BR 2004011245	A	20060718	BR 2004-11245	20040607
JP 2007500750	T	20070118	JP 2006-533613	20040607
NO 2005005750	A	20060106	NO 2005-5750	20051205
US 2006148857	A1	20060706	US 2005-560016	20051208
PRIORITY APPLN. INFO.:			US 2003-477972P	P 20030612
			US 2003-497787P	P 20030826
			WO 2004-US18180	W 20040607

OTHER SOURCE(S): CASREACT 142:155815; MARPAT 142:155815
GI

L3 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB Title compds. I [wherein n = 0-2; m = 0 or 1; X = NH, O or alkylene; Y = C(O), S(O) or S(O)2; R, R1 independently = halo, haloalkyl, alk(en/yn)yl, cycloalkyl, cyano, nitro or azido; p, q = 0-5; A = (hetero)aryl; R6 = H, alkyl, alkoxy, amino or oxo; R7 = H or alkyl; etc., or salts, solvates and physiol. functional derivs. thereof], which are useful in the treatment of human papillomavirus (HPV) infection, were prepared For example, 6-Chloro-2,3,4,9-tetrahydro-1H-carbazol-1-amine was reacted with picolinoyl chloride to give II as a racemate in 63% yield, which was then separated into two pure enantiomers. I showed inhibitory activity against W12 cell line containing HPV16 DNA (10 nM for II, 5 nM for(R)-II and 6000 nM for (S)-II). Therefore, I and pharmaceutical compns. thereof are useful in the treatment or prophylaxis of conditions or diseases due to HPV infection, such as cancer.

IT 827590-44-3P 827590-77-2P 827591-00-4P
827591-06-0P
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(drug candidate; preparation of tetrahydrocarbazoles useful in the treatment of human papillomavirus infection)

RN 827590-44-3 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827590-77-2 CAPLUS
CN Benzamide, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 827591-00-4 CAPLUS
CN 2-Pyridinecarboxamide, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 827591-06-0 CAPLUS
CN Benzamide, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2-fluoro- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 827590-45-4P 827590-46-5P 827590-79-4P
827590-81-8P 827591-02-6P 827591-08-2P
827591-10-6P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of tetrahydrocarbazoles useful in the treatment of human papillomavirus infection)

RN 827590-45-4 CAPLUS
CN Benzamide, N-[(1R)-6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827590-46-5 CAPLUS
CN Benzamide, N-[(1S)-6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827590-79-4 CAPLUS
CN Benzamide, N-[(1R)-6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827590-81-8 CAPLUS
CN Benzamide, N-[(1S)-6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827591-02-6 CAPLUS
CN 2-Pyridinecarboxamide, N-[(1R)-6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L3 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827591-08-2 CAPLUS
CN Benzamide,
N-[(1R)-6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl]-2-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827591-10-6 CAPLUS
CN Benzamide,
N-[(1S)-6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl]-2-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 827590-39-6P 827590-40-9P 827590-41-0P
827590-42-1P 827590-43-2P 827590-47-6P
827590-48-7P 827590-49-8P 827590-50-1P
827590-51-2P 827590-52-3P 827590-53-4P

L3 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
827590-54-5P 827590-55-6P 827590-56-7P
827590-57-8P 827590-58-9P 827590-59-0P
827590-61-4P 827590-63-6P 827590-65-8P
827590-67-0P 827590-69-2P 827590-71-6P
827590-73-8P 827590-75-0P 827590-83-0P
827590-85-2P 827590-87-4P 827590-89-6P
827590-91-0P 827590-94-3P 827590-96-5P
827590-98-7P 827591-04-8P 827591-12-8P
827591-14-0P 827591-17-3P 827591-19-5P
827591-21-9P 827591-23-1P 827591-25-3P
827591-28-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of tetrahydrocarbazoles useful in the treatment
of human papillomavirus infection)

RN 827590-39-6 CAPLUS
CN Urea, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-N'-phenyl- (9CI) (CA INDEX NAME)



RN 827590-40-9 CAPLUS
CN Urea,
N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-N'-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827590-41-0 CAPLUS
CN Urea, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-N'-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 827590-42-1 CAPLUS
CN Urea, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-N'-(3-chloro-4-methoxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827590-43-2 CAPLUS
CN Urea, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-N'-(4-(dimethylamino)phenyl)- (9CI) (CA INDEX NAME)



RN 827590-47-6 CAPLUS
CN Benzeneacetamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



L3 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 827590-48-7 CAPLUS
CN Benzenepropanamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-(9CI)
(CA INDEX NAME)



RN 827590-49-8 CAPLUS
CN 2-Propenamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-3-phenyl-(9CI) (CA INDEX NAME)



RN 827590-50-1 CAPLUS
CN Carbamic acid, (6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 827590-51-2 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2,6-dichloro-(9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827590-52-3 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-fluoro-(9CI)
(CA INDEX NAME)



RN 827590-53-4 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-methoxy-(9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827590-54-5 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-nitro- (9CI) (CA INDEX NAME)



RN 827590-55-6 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-chloro-(9CI)
(CA INDEX NAME)

L3 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827590-56-7 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-methyl-(9CI)
(CA INDEX NAME)



RN 827590-57-8 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827590-58-9 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-3-fluoro-(9CI)
(CA INDEX NAME)



RN 827590-59-0 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-3-methoxy-(9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827590-65-8 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2-methoxy-(9CI) (CA INDEX NAME)



RN 827590-67-0 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2-nitro- (9CI) (CA INDEX NAME)



RN 827590-69-2 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2-chloro-(9CI)

L3 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827590-61-4 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-3-methyl-(9CI)
(CA INDEX NAME)



RN 827590-63-6 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2-fluoro-(9CI)
(CA INDEX NAME)

L3 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(CA INDEX NAME)



RN 827590-71-6 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2-methyl-(9CI)
(CA INDEX NAME)



RN 827590-73-8 CAPLUS
CN Benzamide, N-(2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 827590-75-0 CAPLUS
CN Benzamide, N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827590-83-0 CAPLUS
CN Benzenesulfonamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-methyl- (9CI) (CA INDEX NAME)



RN 827590-85-2 CAPLUS
CN 2-Pyridinecarboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 827590-87-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827590-94-3 CAPLUS
CN Urea, N-phenyl-N'-(2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 827590-96-5 CAPLUS
CN Urea, N-phenyl-N'-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



RN 827590-98-7 CAPLUS
CN Urea, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-N'-phenyl- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



541 /276.7

RN 827590-89-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-6-chloro- (9CI) (CA INDEX NAME)



RN 827590-91-0 CAPLUS
CN 4-Pyridinecarboxamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827591-04-8 CAPLUS
CN 2-Pyridinecarboxamide, N-[(1S)-6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 827591-12-8 CAPLUS
CN 1H-Imidazole-5-carboxamide, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-1-methyl- (9CI) (CA INDEX NAME)



RN 827591-14-0 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-1-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



1,2 548/364.7

RN 827591-17-3 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-1-methyl- (9CI) (CA INDEX NAME)



1,2

RN 827591-19-5 CAPLUS
CN 1H-Imidazole-4-carboxamide, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 827591-25-3 CAPLUS
CN Benzenesulfonamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 827591-28-6 CAPLUS
CN Benzenesulfonamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2-fluoro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L3 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



1,3 548/311.4

RN 827591-21-9 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



1,2

RN 827591-23-1 CAPLUS
CN Benzamide, N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2,6-difluoro- (9CI) (CA INDEX NAME)



548/439

L3 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:392911 CAPLUS
DOCUMENT NUMBER: 141:349995
TITLE: Synthesis and Neurotropic Activity of 1-Ureido-1,2,3,4-Tetrahydrocarbazoles
AUTHOR(S): Bokanov, A. I.; Kukushkin, S. Yu.; Parshin, V. A.; Alekseeva, L. M.; Kobrakov, K. I.; Granik, V. G.
CORPORATE SOURCE: Research Institute of Organic Intermediates and Dyes, State Scientific Center of the Russian Federation, Moscow, Russia
SOURCE: Pharmaceutical Chemistry Journal (Translation of Khimiko-Farmatsevticheskii Zhurnal) (2004), 38(1), 10-14
CODEN: PCJOAU; ISSN: 0091-150X
PUBLISHER: Kluwer Academic/Consultants Bureau
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:349995
GI



AB The title compds. I (R = CONH2, CONHBu, CONHCH2CO2H, C(S)NH2; R1= H, Me) were prepared by reaction of the corresponding tetrahydrocarbazol-1-ol with H2NCONHR. I showed moderate anticonvulsant and antihypoxant activity.

IT 352549-63-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and neurotropic activity of 1-ureido-1,2,3,4-tetrahydrocarbazoles)

RN 352549-63-4 CAPLUS
CN Urea, (2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L3 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:182363 CAPLUS
DOCUMENT NUMBER: 140:229400
TITLE: Methods for identifying modulators of bromodomain activity and for treating HIV infections
INVENTOR(S): Zhou, Ming-Ming; Aggarwal, Aneel K.; Verdin, Eric; Ott, Melanie
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 515 pp., Cont.-in-part of U.S. Ser. No. 510,314.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004043378	A1	20040304	US 2001-784553	20010216
US 2004009613	A1	20040115	US 2002-209201	20020731
PRIORITY APPLN. INFO.:			US 2000-510314 A2	20000222
			US 2001-784553 A3	20010216

AB The ZA loop of various bromodomain proteins and nucleic acids encoding them are disclosed. These ZA loop peptides may be used for identifying compds. which modulate the affinity of bromodomains for acetyllysine-containing ligands, e.g., the affinity of P300/CBP-associated factor (P/CAF) for Tat acetylated at lysine-50. Such P/CAR-acetyl-Tat complex-modulating substances may be used to treat HIV infections. Thus, the structural determination of a P/CAF bromodomain and of PCAF bromodomain complexed with acetylhistamine or with an acetylated peptide derived from Tat were determined by NMR spectroscopy. P/CAF residues crucial to the P/CAF binding of acetyllysine were identified.
IT 646034-72-2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(acetyl-lysine analog, bromodomain ligand; methods for identifying modulators of bromodomain activity and for treating HIV infections)
RN 646034-72-2 CAPLUS
CN Acetamide, N-(2,3,4,9-tetrahydro-6-methoxy-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



L3 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:41029 CAPLUS
DOCUMENT NUMBER: 140:105223
TITLE: The three-dimensional structure of a bromodomain, methods of identifying modulators of bromodomains, and uses in drug discovery, particularly anti-AIDS
INVENTOR(S): Zhou, Ming-Ming; Aggarwal, Aneel K.; Verdin, Eric; Ott, Melanie
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 80 pp., Division of U.S. Ser. No. 784,553.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004009613	A1	20040115	US 2002-209201	20020731
US 2004043378	A1	20040304	US 2001-784553	20010216
PRIORITY APPLN. INFO.:			US 2000-510314 A	20000222
			US 2001-784553 A3	20010216

AB The present invention provides the structural determination of a bromodomain determined by NMR spectroscopy. The invention provides the three-dimensional structure of a bromodomain as well as the three-dimensional structure of a bromodomain-acetyl-histamine complex. The invention provides, for the first time, that bromodomains bind to acetyl-lysine residues of proteins. The invention also provides structural insights into HIV-1 gene transcription activation by Tat via P/CAF histone acetyltransferase chromatin remodeling. The invention provides the structural determination of the Tat-P/CAF bromodomain binding complex determined by NMR spectroscopy. The invention also provides binding partners for the bromodomain. In addition, the present invention provides methodol. for related drug discovery using high throughput drug screening or structure based rational drug design using the three-dimensional data. In a particular embodiment, the three-dimensional structural information is used in the identification and/design of an inhibitor of leukemia. In another embodiment, the three-dimensional structural information is used in the identification and/design of an inhibitor of HIV-1 infection and/or AIDS.
IT 646034-72-2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(acetyl-lysine analog, bromodomain ligand; three-dimensional structure of bromodomain, methods of identifying modulators of bromodomains, and uses in drug discovery, particularly anti-AIDS)
RN 646034-72-2 CAPLUS
CN Acetamide, N-(2,3,4,9-tetrahydro-6-methoxy-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L3 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:21702 CAPLUS
DOCUMENT NUMBER: 140:263755
TITLE: A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells
AUTHOR(S): Kau, Tweeny R.; Schroeder, Frank; Ramaswamy, Shivapriya; Wojciechowski, Cheryl L.; Zhao, Jean J.; Roberts, Thomas M.; Clardy, Jon; Sellers, William R.; Silver, Pamela A.
CORPORATE SOURCE: Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA
SOURCE: Cancer Cell (2003), 4(6), 463-476
CODEN: CCAECI; ISSN: 1535-6108
PUBLISHER: Cell Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The PI3K/PTEN/Akt signal transduction pathway plays a key role in many tumors. Downstream targets of this pathway include the Forkhead family of transcription factors (FOXO1a, FOXO3a, FOXO4). In PTEN null cells, FOXO1a is inactivated by PI3K-dependent phosphorylation and mislocalization to the cytoplasm, yet still undergoes nucleocytoplasmic shuttling. Since forcible localization of FOXO1a to the nucleus can reverse tumorigenicity of PTEN null cells, a high-content, chemical genetic screen for inhibitors of FOXO1a nuclear export was performed. The compds. detected in the primary screen were retested in secondary assays, and structure-function relationships were identified. Novel general export inhibitors were found that react with CRM1 as well as a number of compds. that inhibit PI3K/Akt signaling, among which are included multiple antagonists of calmodulin signaling.
IT 413593-64-3
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(chemical genetic screen identifies inhibitors of regulated nuclear export of Forkhead transcription factor in PTEN-deficient tumor cells)
RN 413593-64-3 CAPLUS
CN Acetamide, 2-chloro-N-(2,3,4,9-tetrahydro-6-methyl-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L3 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:447164 CAPLUS
DOCUMENT NUMBER: 133:97074
TITLE: Crystal structure of N-(1,2,3,4-tetrahydrocarbazole-1-yl)-2-methoxyacetamide
AUTHOR(S): Hokelek, Tuncer; Patir, Suleyman
CORPORATE SOURCE: Department of Physics, Hacettepe University, Beytepe-Ankara, 06532, Turk.
SOURCE: Analytical Sciences (2000), 16(6), 665-666
CODEN: ANSCEN; ISSN: 0910-6340
PUBLISHER: Japan Society for Analytical Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Crystals of the title compound are monoclinic, space group P21/n , with a 8.083(1), b 10.092(1), c 16.951(2) Å, β 102.78(2)°; Z = 4, dc = 1.272; R = 0.045, Rw = 0.055 for 2472 reflections. Atomic coordinates are given. The mol. consists of a carbazole skeleton and methoxyacetamide chain at position 1. The rings A and B are close to planar; ring C (with the methoxyacetamide group) has a sofa conformation.
IT 282101-68-2, N-(1,2,3,4-Tetrahydrocarbazole-1-yl)-2-methoxyacetamide
RL: PRP (Properties)
(crystal structure of)
RN 282101-68-2 CAPLUS
CN Acetamide, 2-methoxy-N-(2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:176132 CAPLUS
DOCUMENT NUMBER: 123:169467
TITLE: Carbazole derivatives with antimycobacterial activity
AUTHOR(S): Mahboobi, Siavosh; Kuhr, Sabine; Meindl, Wolfgang
CORPORATE SOURCE: Inst. Pharm., Univ. Regensburg, Regensburg, D-93040, Germany
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1994), 327(10), 611-17
CODEN: ARPMAS; ISSN: 0365-6233
DOCUMENT TYPE: Journal
LANGUAGE: German
GI



I



II

AB Carbazoles are synthesized and tested for antimycobacterial properties. The different antimycobacterial properties of diastereomers are examined using I; those of a racemic compound and the (+)-enantiomer are tested with (±)- and (+)-1-(hexylamino)-1-phenylheptane and with (±)- and (+)-II. (+)-1-(Hexylamino)-1-phenylheptane is prepared by enantioselective synthesis.
IT 167476-85-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(carbazoles with antimycobacterial activity)
RN 167476-85-9 CAPLUS
CN Benzenesulfonamide, N-(2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



Y = SO2 p = 0
t = 0
A = ph
q = 0
provisional

L3 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1993:472901 CAPLUS
DOCUMENT NUMBER: 119:72901
TITLE: Syntheses of iso-condensed heteroaromatic pyrroles and their application to the total syntheses of natural products
AUTHOR(S): Sha, Chin Kang; Tsou, Chiu Peng; Tsai, Chung Yin; Liu, Jia Ming; Lee, Ren Sheng; Yang, Jeng Fenn
CORPORATE SOURCE: Dep. Chem., Natl. Tsing Hua Univ., Hsinchu, 30043, Taiwan
SOURCE: Youji Huaxue (1993), 13(2), 162-5
CODEN: YCHHDX; ISSN: 0253-2786
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 119:72901
GI



I



II



III

AB A novel method, namely the intramol. 1,3-dipolar cycloaddn. and cycloreversion of azidoalkylidenemalonates, e.g. I, for the preparation of iso-condensed heteroarom. pyrroles was developed. The application of this method for the synthesis of 2,4-dihydropyrrolo[3,4-b]indole ring system II as well as the application of this ring system for the total syntheses of ellipticine III is reported.
IT 146253-32-9P 146253-33-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and aromatization of)
RN 146253-32-9 CAPLUS
CN Carbamic acid, (6,11-dihydro-5,11-dimethyl-5H-pyrido[4,3-b]carbazol-5-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 146253-33-0 CAPLUS
CN Carbamic acid, (10,11-dihydro-5,11-dimethyl-5H-pyrido[3,4-b]carbazol-11-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 146253-30-7P 146253-31-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrogenation of)
RN 146253-30-7 CAPLUS
CN Carbamic acid, (6,11-dihydro-5-methyl-11-methylene-5H-pyrido[4,3-b]carbazol-5-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 146253-31-8 CAPLUS
CN Carbamic acid, (10,11-dihydro-11-methyl-5-methylene-5H-pyrido[3,4-b]carbazol-11-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L3 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:124852 CAPLUS
DOCUMENT NUMBER: 118:124852
TITLE: Total syntheses of ellipticine alkaloids and their amino analogs
AUTHOR(S): Sha, Chin Kang; Yang, Jeng Fenn
CORPORATE SOURCE: Dep. Chem., Natl. Tsing Hua Univ., Hsinchu, 30043, Taiwan
SOURCE: Tetrahedron (1992), 48(48), 10645-54
CODEN: TETRAB; ISSN: 0040-4020
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 118:124852
GI



AB Staudinger reaction of indole I with triphenylphosphine gave 2,4-dihydropyrrolo[3,4-b]indole II (R = H). Treatment of II (R = H) with di-tert-Bu dicarbonate and 4-dimethylaminopyridine gave II (R = CO2CMe3). Diels-Alder reaction of II (R = CO2CMe3) with 3,4-pyridyne gave cycloadducts III (X = N, Z = CH; X = CH, Z = N), which were converted into ellipticine (IV) and isoellipticine. New amino analogs of ellipticine were also synthesized by this new route.
IT 146253-32-9P 146253-33-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deamination of)
RN 146253-32-9 CAPLUS
CN Carbamic acid, (6,11-dihydro-5,11-dimethyl-5H-pyrido[4,3-b]carbazol-5-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 146253-33-0 CAPLUS
CN Carbamic acid, (10,11-dihydro-5,11-dimethyl-5H-pyrido[3,4-b]carbazol-11-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 146253-30-7P 146253-31-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrogenation of)
RN 146253-30-7 CAPLUS
CN Carbamic acid, (6,11-dihydro-5-methyl-11-methylene-5H-pyrido[4,3-b]carbazol-5-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 146253-31-8 CAPLUS
CN Carbamic acid, (10,11-dihydro-11-methyl-5-methylene-5H-pyrido[3,4-b]carbazol-11-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L3 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1992:469729 CAPLUS
DOCUMENT NUMBER: 117:69729
TITLE: Substituted 1,2,3,4-tetrahydrocyclopent[b]indoles, 1,2,3,3a,4,8a-hexahydrocyclopent[b]indoles and related compounds
INVENTOR(S): Ong, Helen H.; O'Malley, Gerard J.; Merriman, Michael C.; Palermo, Mark G.
PATENT ASSIGNEE(S): Hoechst-Roussel Pharmaceuticals Inc., USA
SOURCE: U.S., 22 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5100891	A	19920331	US 1991-642952	19910118
US 5192789	A	19930309	US 1992-818703	19920109
RO 112505	B1	19971030	RO 1992-149168	19920115
FI 9200192	A	19920719	FI 1992-192	19920116
FI 102174	B	19981030		
FI 102174	B1	19981030		
PL 167465	B1	19950930	PL 1992-296651	19920116
PL 169417	B1	19960731	PL 1992-293209	19920116
CZ 282732	B6	19970917	CZ 1992-129	19920116
CA 2059610	A1	19920719	CA 1992-2059610	19920117
CA 2059610	C	20020402		
NO 9200235	A	19920720	NO 1992-235	19920117
NO 178397	B	19951211		
NO 178397	C	19960320		
AU 9210279	A	19920723	AU 1992-10279	19920117
AU 650315	B2	19940616		
ZA 9200341	A	19920930	ZA 1992-341	19920117
JP 04334367	A	19921120	JP 1992-6681	19920117
HU 67027	A2	19950130	HU 1992-172	19920117
RU 2077530	C1	19970420	RU 1992-5010763	19920117
EP 496314	A1	19920729	EP 1992-100816	19920118
EP 496314	B1	19971001		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT, SE				
AT 158790	T	19971015	AT 1992-100816	19920118
ES 2109953	T3	19980201	ES 1992-100816	19920118
BR 9200171	A	19921006	BR 1992-171	19920121
US 5298626	A	19940329	US 1992-976067	19921113
US 5472975	A	19951205	US 1994-177035	19940104
US 5514700	A	19960507	US 1995-472586	19950607
FI 9700396	A	19970130	FI 1997-396	19970130
FI 107150	B1	20010615		
FI 9700397	A	19970130	FI 1997-397	19970130
FI 106713	B1	20010330		
FI 2000001775	A	20000810	FI 2000-1775	20000810
FI 107919	B1	20011031		

PRIORITY APPLN. INFO.: US 1991-642952 A2 19910118

IDS

L3 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

	US 1992-818703	A3 19920109
	FI 1992-192	A 19920116
	US 1992-976067	A3 19921113
	US 1994-177035	A3 19940104

OTHER SOURCE(S): CASREACT 117:69729; MARPAT 117:69729
GI



AB Title compds. I [n = 2, 3, 4, 5; X = H, lower alkyl, lower alkoxy, OH, halo, CF3, NO2; R1 = H, lower alkyl, lower alkenyl, lower alkynyl, amino lower alkyl, cycloalkyl, cycloalkenyl, aryl, pyrrolidinoalkyl, piperidinoalkyl, morpholinoalkyl, etc.; R2 = H, lower alkyl, formyl, lower alkylcarbonyl, benzyloxycarbonyl, etc.; NR1R2 = pyrrolidino, piperidino, morpholino, piperazino, etc.; R3 = H, lower alkyl, aryl lower alkyl, lower alkylcarbonyl, lower alkoxycarbonyl; R4 = O2CNR5R6 (R5 = lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, aryl, etc.; R6 = H, lower alkyl, aryl, aryl lower alkyl; NR5R6 = pyrrolidino, piperidino, morpholino, piperazino, etc.)] were prepared as agents for alleviating various memory dysfunctions characterized by a cholinergic deficit such as Alzheimer's disease. Thus, 1,2-dihydrocyclopent[b]indol-3(2H)-one II (R7 = H) was acylated with ClCH2COCl in the presence of AlCl3 in CH2Cl2 to give II (R7 = ClCH2CO), which was oxidized with m-chloroperbenzoic in the presence of Na phosphate in CHCl3 to give II (R7 = ClCH2CO2). The latter was treated with cyclopropylamine in the presence of TiCl4 in toluene to give the imine III, which was reduced with NaBH4 in Me2CHOH/MeOH (5:1) to give the amine IV (R8 = H), which was treated with Me isocyanate in the presence of 1,8-diazabicyco[5.4.0]undec-7-ene in CH2Cl2 to give IV (R8 = MeNHCO) (V). V at 3.5 μM inhibited brain acetylcholinesterase by 50%; V also inhibited monoamine oxidases.

IT 142283-84-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

L3 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(Reactant or reagent)
(prepn. and borane redn. of)

RN 142283-84-9 CAPLUS
CN Carbamic acid, (1,2,3,4-tetrahydrocyclopent[b]indol-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



V = -C-
X = OCH2 X
not claimed

L3 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1973:546322 CAPLUS
DOCUMENT NUMBER: 79:146322
TITLE: Reactions between arenesulfonyl azides and tetrahydrocarbazoles
AUTHOR(S): Bailey, A. Sydney; Buckley, Alan J.; Seager, John F.
CORPORATE SOURCE: Dyson Perrins Lab., Univ. Oxford, Oxford, UK
SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1973), (17), 1809-18
CODEN: JCPRB4; ISSN: 0300-922X
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB The spiro compound (I) in F3CCO2H gave 1,2,3,4,4a,9a-hexahydro-9-methyl-4a-(p-tolylsulfonylamino)-9a-(trifluoroacetoxy)carbazolium trifluoroacetate which with Na2CO3 gave 2,3,4,4a-tetrahydro-9-methyl-4a-(p-tolylsulfonylamino)carbazole. The latter was an intermediate in the reaction of 4-MeC6H4SO2N3 and 9-methyltetrahydrocarbazole (II). Tetrahydrocarbazoles with arenesulfonyl azides in base gave cyclopentenoquinolines, e.g. II with 4-ClC6H4SO2N3 gave 80% imine (III). 1-Methyltetrahydrocarbazole with 4-Me- and 4-ClC6H4SO2N3 gave imine IV (R = Me and Cl, resp.). 1,9-Dimethyltetrahydrocarbazole with 4-MeC6H4SO2N3 gave sulfonamide V. The kinetics of the acid-catalyzed rearrangement of I were studied.
IT 50528-03-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 50528-03-5 CAPLUS
CN Benzenesulfonamide, 4-methyl-N-(2,3,4,9-tetrahydro-1H-carbazol-1-yl)- (9CI) (CA INDEX NAME)



proviso